THE NONLIPID AND ANTI-INFLAMMATORY EFFECTS OF ROSUVASTATIN IN CARDIAC RECIPIENTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The non-lipid effects of rosuvastatin (Mertinil) were studied in patients after heart transplantation, which were evaluated from the time course of changes in the levels of C-reactive protein (CRP) and biomarkers for a risk of graft vasculopathy. In cardiac recipients, rosuvastatin (Mertinil) was found to produce both lipid-lowering and anti-inflammatory effects (a reduction in CRP levels); its intake promotes a decrease in the biomarkers (PAPP-A and sCD40L) of a risk for cardiac graft vasculopathy.

Full Text

Restricted Access

References

  1. Болезнь коронарных артерий пересаженного сердца. Под ред. В.И. Шумакова / М.: ООО «Медицинское информационное агентство». - 208; 160 с.
  2. Шевченко А.О., Шевченко О.П. Эффективность и безопасность розувастатина в суточной дозе 5 мг // Врач. - 2011; 9: 30-3.
  3. Abu-Qaoud M.S., Stoletniy L.N., Chen D. et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients // Transplantation. - 2012; 94 (9): 965-70.
  4. Aharinejad S., Krenn K., Zuckermann A. et al. Matrix metalloproteinases and their tissue inhibitor in cardiac transplantation // Eur. J. Cardiothorac. Surg. - 2007; 32: 48-51.
  5. Furman C., Copin C., Kandoussi M. et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability // Atherosclerosis. - 2004; 174: 93-8.
  6. Gazi I., Liberopoulos E., Athyros V. et al. Statins and solid organ transplantation // Curr. Pharm. Des. - 2006; 12: 4771-83.
  7. Kobashigawa J., Moriguchi J., Laks H. et al. Ten-year follow- up of a randomized trial of pravastatin in heart transplant patients // J. Heart Lung. Transplant. - 2005; 24: 1736-40.
  8. Kobashigawa J. Statins and cardiac allograft vasculopathy after heart transplantation // Sem. Vasc. Med. - 2004; 4: 401-6.
  9. Mehra M., Raval N. Metaanalysis of statins and survival in de novo cardiac transplantation // Transplant. Proc. - 2004; 36: 1539-41.
  10. Segovia J., Gomez-Bueno M., Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation // Exp. Opin. Pharmacother. - 2006; 7: 2369-83.
  11. Shevchenko O.P., Khalilulin T.A., Shevchenko A.O. et al. Comparision of predictive significance of soluble CD40ligand, pregnancy-associated plasma protein A, and placental growth factor for graft failure development after heart transplantation // J. Heart Lung. Transplant. - 2012; 31 (4S): 172-3.
  12. Stein W., Schrepfwer S., Iton S. et al. Prevention of transplant coronary artery disease by prenylation inhibitors // J. Heart Lung. Transplant. - 2011; 30: 761-9.
  13. Suzuki J., Isobe M., Kawauchi M. et al. Altered expression of matrix metalloproteinases and tissue inhibitors of metal-loproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates // Transplant. Int. - 2000; 13: 106-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies